The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-30

Study Completion Date

2021-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot randomized, controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine the feasibility of a future full-scale RCT exploring if oral administration of vitamin D3 could reduce the risk of subsequent Peritoneal dialysis-related (PD-related) peritonitis.

Aims of the study:

Aim 1: To determine the feasibility of oral vitamin D supplementation among PD patients who have recovered from a recent episode of peritonitis.

Aim 2: To examine the effect of vitamin D supplementation on the risk for peritonitis among patients on peritoneal dialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D3 Supplementation in Dialysis Patients

NCT01312714

End-Stage Renal Disease

COMPLETED PHASE2

Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects

NCT00427037

Chronic Kidney Disease Vitamin D Deficiency

COMPLETED NA

Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease

NCT00511225

End Stage Renal Disease

COMPLETED NA

Vitamin D Supplementation in Older Adults With Urinary Incontinence

NCT01971801

Urinary Incontinence Vitamin D Deficiency

COMPLETED NA

Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy

NCT02489240

Contrast-induced Nephropathy

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be screened for eligibility one month after the onset of PD-related peritonitis, those who meet the inclusion criteria will be enrolled in this study.

All consenting participants will be randomized into the vitamin D treatment group or the control group, general information and baseline biochemistry data would be collected. Patients in the treatment group will be treated with oral Cholecalciferol (2000IU/day) apart from routine treatment for PD. Those in the control group will receive routine treatment for PD. Both groups will be followed for 12 months. During the observational period, any onset of subsequent peritonitis will be recorded, serum 25(OH)D, biochemical indices will be measured every 3 months. Follow up would take place frequently, any outcome events would be recorded.

Aims and hypotheses:

Aim 1: To determine the feasibility of oral vitamin D supplementation among PD patients who have recovered from a recent episode of peritonitis.

Hypothesis1: A large、full-scale randomized controlled trail on the effects of oral vitamin D on the risk for peritonitis among PD patients is feasible.

Aim 2: To examine the effect of vitamin D supplementation on the risk for peritonitis among patients on peritoneal dialysis.

Hypothesis 2: Oral supplementation of vitamin D will reduce the risk of subsequent peritoneal dialysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peritoneal Dialysis-associated Peritonitis Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD

Group Type EXPERIMENTAL

Cholecalciferol (2000iu qd)

Intervention Type DRUG

Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD

Routine therapy for PD

Intervention Type OTHER

Patients randomized to the placebo group will receive routine therapy for PD.

Control group

Patients randomized to the placebo group will receive routine therapy for PD.

Group Type PLACEBO_COMPARATOR

Routine therapy for PD

Intervention Type OTHER

Patients randomized to the placebo group will receive routine therapy for PD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cholecalciferol (2000iu qd)

Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD

Intervention Type DRUG

Routine therapy for PD

Patients randomized to the placebo group will receive routine therapy for PD.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Natural Vitamin D3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Medically stable and receiving peritoneal dialysis (PD) for\>1 months
2. Age at least 18 years.
3. Serum 25(OH)D\<75nmol/l (30ng/ml)
4. Adequate dialysis on evaluation, weekly Kt/V ≥ 1.5 and no clinical uremic symptoms

Exclusion Criteria

1. Receive Vitamin D2/D3 or drugs known to alter serum 25-hydroxyvitamin D (25(OH)D) levels during the previous 12 months;
2. History of allergic reaction to Cholecalciferol;
3. Current or past malignant disease, active hepatitis or hepatic failure, acute systemic infection, active autoimmune diseases, severe digestive malabsorption or eating disorder, HIV/AIDS;
4. A high probability (assessed by the recruiting physician) of receiving a kidney transplant or transferring to hemodialysis (HD) or drop-out due to socioeconomic causes within 6 months;
5. Pregnant or breastfeeding;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No